Melanocyte stem cells

Friday, June 17th, 2011

Human skin consists of a number of different cells. The majority of the top layer of the skin is made up of keratinocytes which are produced constantly and migrate to the surface of the skin where they ‘slough off’ as dead skin.

Melanocytes, the cells which produce pigment in the skin, lie below the keratinocytes at the base of the epidermis (see the figure, click to enlarge). Melanocytes also exist at the root of the hair follicle, in the matrix of the inner root sheath or shaft, and are responsible for giving hair its colour. The dermis, the layer of the skin beneath the epidermis, consists mostly of collagen, elastic tissue and reticulum fibres, along with some specialised nerves and glands. The bases of hair follicles are also embedded in this middle layer of skin.

(more…)

Bookmark and Share

Stem cells: potential for regeneration

Tuesday, June 14th, 2011

Stem cells are immature, unspecialised cells which have the ability to develop into other adult cells with a specific function, i.e. skin cells, red blood cells, nerve cells (neurons), etc.

Stem cells have two important properties:

  1. They are capable of renewing themselves indefinitely, i.e. they can divide many times to produce lots of other stem cells.
  2. They have the ability to differentiate. This means that they can grow and mature into a specialised cell. Differentiation may involve changes in the cell’s size, shape, interaction with their surrounding environment and activity/function. This process requires external stimulation from chemical factors, or other cells, to activate and regulate the development of stem cells into specialised cells when they are needed.

(more…)

Bookmark and Share

The challenges of ‘orphan’: can drug development cope with rare diseases?

Thursday, June 9th, 2011

Scarcely a day goes by that the Clinuvel team is not contacted regarding the latest conference: everything from monitoring to manufacturing to marketing is analysed, discussed and disputed across the globe in conference form. It’s impossible – and unwise – for small companies to try to attend all these forums, but it is equally impossible to work in the space without looking outside the office door: there is much to be learned from what others have done or not done to succeed in an industry fraught with failure.

And indeed there was much to take on at the recent World Orphan Drug Summit, held in Frankfurt last week. (more…)

Bookmark and Share

Cellular messaging leading to melanin production

Tuesday, June 7th, 2011

Each cell within the body has one or more receptors; molecules on or within the cell to which other molecules, called ligands, bind. This binding causes a series of chemical reactions within the cell, called a ‘signaling pathway’. Signaling pathways are responsible for cellular responses, allowing other cells and external elements to alter how a cell functions. There are two types of ligands which bind to receptors: agonists, which then promote a response in the pathway, and antagonists, which lead to an alternate response. (more…)

Bookmark and Share

At what cost, expertise?

Thursday, May 26th, 2011

Drug development is time consuming, expensive and fraught with risk. Setting aside commercial considerations, the scientific rational for the use of a drug and its introduction into the clinic requires a deep level of scientific and medical understanding in an environment which is continuously changing. The less common the drug class or clinical indication, the less likely one is to find individual experts who have the capacity  to properly evaluate whether a drug is safe and effective for use in a clinical setting. Here one needs to learn while progressing, learning on the job due to lack of precedent.

If one identifies scientific experts in the field of interest, they are likely to be highly specialised physicians and basic scientists; often these experts will want to be involved on a potential breakthrough by accessing the prospective and novel therapy in their field of expertise. (more…)

Bookmark and Share

“Solariums make a mockery of our efforts to reduce skin cancer”: Cancer Council Australia

Monday, May 16th, 2011

Cancer Council Australia has launched one of the strongest public attacks to date on the use and regulation of sunbeds in the country. This follows a report that some solarium devices emit UV radiation six times stronger than the sun at midday in Australia.

In a press release issued today, the CEO of Cancer Council Australia, Professor Ian Olver, cited a paper published in this month’s Photochemistry and Photobiology journal when calling for the Australian Government to phase out solariums. (more…)

Bookmark and Share

Porphyrias: a disease grouping by cause, not symptoms

Monday, April 18th, 2011

Held biennially, the Porphyrins & Porphyrias conference (P&P) is the world’s largest gathering on the porphyrias – a group of metabolic disorders causing biochemical disruptions in the pathway of the body which synthesizes haem (heme).

As a result of each of these disruptions, the body presents with unique symptoms ranging from skin symptoms and phototoxicity – as those seen in erythropoietic protoporphyria and congenital erythropoietic porphyria – through to acute attacks of abdominal pain, seen most commonly in acute intermittent porphyria. In short, no two porphyrias are clinically identical yet they are discussed as a single group of disorders with a similar cause. As a matter of fact, there are eight variations of porphyrias, each with a specific clinical manifestation of disease. (more…)

Bookmark and Share

How does indoor tanning cause skin cancer?

Wednesday, April 6th, 2011

Tanning causes skin cancerEarlier today, new stats were published by Cancer Research UK highlighting that two young adult Britons are diagnosed with skin cancer every day; a rate which has tripled since the 1970s. There were several factors highlighted as contributing to this increase, but one was most clearly singled out in the release:

“using a sunbed before the age of 35 can increase your risk of melanoma by 75%”

(more…)

Bookmark and Share

‘Measuring’ vitiligo: the challenges of clinical and treatment evaluation

Monday, April 4th, 2011

Since our announcement last year that Clinuvel would commence a new program for SCENESSE® (afamelanotide) in nonsegmental vitiligo, the company has received vast interest in the application of the drug in this disease. Of the enquiries that best captured the essence of this program, one stood out: a US based analyst asked how the company intended to objectively measure the response to treatment, the repigmentation of vitiliginous lesions, in its trial. (more…)

Bookmark and Share

The skin on your palms and soles

Tuesday, March 29th, 2011

Have you ever wondered why the palms of your hands and the soles of your feet are lighter than the rest of your skin? Or why the skin in these areas is thicker than on other parts of your body? Researchers from the department of Geriatric and Environmental Dermatology at Nagoya City University in Japan may well have found the answer.

(more…)

Bookmark and Share